Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC—Real World Efficacy

Mette T. Mouritzen, Andreas Carus, Morten Ladekarl, Peter Meldgaard, Anders W. M. Nielsen, Anna Livbjerg, Jacob W. Larsen, Halla Skuladottir, Charlotte Kristiansen, Kim Wedervang, Tine Schytte, Karin H. Hansen, Anne-Cathrine Østby, Malene S. Frank, Jakob Lauritsen, Jens B. Sørensen, Seppo W. Langer, Gitte F. Persson, Jon L Andersen, Johanna M. C. FraryLars B. Drivsholm, Charles Vesteghem, Heidi S. Christensen, Birgitte Bjørnhart, Mette Pøhl

Research output: Contribution to journalJournal articleResearchpeer-review

19 Citations (Scopus)
41 Downloads (Pure)


Background The selection of patients with non-small cell lung cancer (NSCLC) for immune checkpoint inhibitor (ICI) treatment remains challenging. This real-world study aimed to compare the overall survival (OS) before and after the implementation of ICIs, to identify OS prognostic factors, and to assess treatment data in first-line (1L) ICI-treated patients without epidermal growth factor receptor mutation or anaplastic lymphoma kinase translocation. Methods Data from the Danish NSCLC population initiated with 1L palliative antineoplastic treatment from 1 January 2013 to 1 October 2018, were extracted from the Danish Lung Cancer Registry (DLCR). Long-term survival and median OS pre-and post-approval of 1L ICI were compared. From electronic health records, additional clinical and treatment data were obtained for ICI-treated patients from 1 March 2017 to 1 October 2018. Results The OS was significantly improved in the DLCR post-approval cohort (n = 2055) compared to the pre-approval cohort (n = 1658). The 3-year OS rates were 18% (95% CI 15.6–20.0) and 6% (95% CI 5.1–7.4), respectively. On multivariable Cox regression, bone (HR = 1.63) and liver metastases (HR = 1.47), performance status (PS) 1 (HR = 1.86), and PS ≥ 2 (HR = 2.19) were significantly associated with poor OS in ICI-treated patients. Conclusion OS significantly improved in patients with advanced NSCLC after ICI implementation in Denmark. In ICI-treated patients, PS ≥ 1, and bone and liver metastases were associated with a worse prognosis.

Original languageEnglish
Article number4846
Issue number19
Publication statusPublished - 28 Sept 2021


  • Advanced lung cancer
  • Anti-PD-1
  • Cancer immunotherapy
  • Clinical prognostic factors
  • Danish registry
  • First-line treatment
  • Immune checkpoint inhibitors
  • Non-small cell lung cancer
  • Overall survival
  • Real-world evidence


Dive into the research topics of 'Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC—Real World Efficacy'. Together they form a unique fingerprint.

Cite this